In a commentary published in the Journal of the American Medical Association, researchers suggest that we must improve how genetic information is used to make breast cancer treatment decisions. The paper is authored by Steven Katz, M.D., M.P.H., Monica Morrow, M.D., and Allison Kurian, M.D., from the Cancer Surveillance and Outcomes Research Team, a multidisciplinary group of investigators at the forefront of understanding how women make decisions about breast cancer treatment. mCancerPartner talked with Dr. Katz about these issues. Continue reading
In 1971 President Nixon signed into law the National Cancer Act which officially launched the “war on cancer.” It earmarked a budget of $100 million towards cancer research and the promise to find new treatments for the second leading cause of death in America at that time.
“One of the most important things that came out of the National Cancer Act is that we started to do a lot of basic science to study the disease … today cancer is thought of as a molecular disease within a cell, whereas in the old days, cancer was thought of as a disease of tumors of tissue,” says Dr. Otis Brawley, chief medical officer for the American Cancer Society.
So where has this science taken us 44 years later? According to the Centers for Disease Control and Prevention, cancer still remains the second leading cause of death after heart disease. However, all is not lost, we’ve come a long way in 44 years!
Unlike the 1970s, when hardly anyone who had cancer was considered a survivor, we now have more than 14 million cancer survivors in the United States, and that number is projected to increase as our baby-boomers age. While survivors are increasing in numbers, we have also made progress in cancer prevention though screening and early detection programs, specifically in colon and cervical cancer.
As Dr. Brawley’s comments above reflect, we have continued to advance our understanding of cancer at the molecular level. This knowledge in turn has led to new developments in targeted therapy, vaccine therapy and immunotherapy. Continue reading